Camprodon-Rosanas E, Pujol J, Martínez-Vilavella G, Blanco-Hinojo L, Medrano-Martorell S, Batlle S, Forns J, Ribas-Fito N, Dolz M, Sunyer J. Brain structure and function in school-aged children with sluggish cognitive tempo symptoms. J Am Acad Child Adolesc Psychiatry. 2019 Feb;58(2):256-96. doi: 10.1016/j.jaac.2018.09.441
Rodriguez-Salas N, Dominguez G, Barderas R, Mendiola M, Garcia-Albeniz X, Maurel J, Batlle JF. Clinical relevance of colorectal cancer molecular subtypes. Crit Rev Oncol Hematol. 2017 Jan;109:9-19. doi: 10.1016/j.critrevonc.2016.11.007
Saigi-Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Choong E, Gholamrezaee M, Magistretti P, Aubry JM, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Kutalik Z, Conus P, Eap CB. Association of PCK1 with body mass index and other metabolic features in patients with psychotropic treatments. J Clin Psychopharmacol. 2015 Oct;35(5):544-52. doi: 10.1097/JCP.0000000000000388
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, Schneeweiss S. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol. 2012 Feb 1;32(1):11-7.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.